Identification, synthesis, and strategy for minimization of potential impurities in the preclinical anti-HBV drug Y101
…, P Cao, C Liu, Z Huang, W Xia, G Liang
文献索引：Lu, Cuong V.; Chen, Jiong J.; Perrault, William R.; Conway, Brian G.; Maloney, Mark T.; Wang, Ying Organic Process Research and Development, 2006 , vol. 10, # 2 p. 272 - 277
... be identified for drugs with a maximum daily dose equal to or lesser than 2 g, and the ... 5. (A) Mixture of intermediate 5, stereoisomer 5-A (2S, 2′R), stereoisomer 5-B (2R, 2′R), and stereoisomer 5 ... entry, base, mole ratio of base, T (°C) a, t R (h) b, yield (%), Y101 (%), stereoisomer ...
